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Abstract
Background: Few data are available on the usefulness of short term treatment with low-medium dose of inhaled
corticosteroids (ICS) in pre-school children with wheezing exacerbations.
Methods: To compare the efficacy of one week treatment with 400 μg b.i.d. nebulized beclomethasone
dipropionate (BDP), plus nebulized 2500 μg prn salbutamol (BDP group), versus nebulized b.i.d. placebo, plus
nebulized prn 2500 μg salbutamol (placebo group), a post-hoc analysis was performed on data obtained in 166
pre-school children with multiple-trigger wheezing, recruited during an acute wheezing episode.
Results: The percentage of symptom-free days (SFDs) was significantly higher in the BDP group (54.7%) than in
the placebo group (40.5%; p = 0.012), with a 35% relative difference. Day-by-day analysis showed that the
percentage of SFDs was already higher in the BDP group after 2 days (7.4%), the difference reaching statistical
significance at day 6 (12.3%; p = 0.035). Cough score was also reduced in the BDP group (0.11) as compared with
the placebo group (0.39; p = 0.048), the difference reaching statistical significance after 5 days of treatment (0.18
and 0.47 respectively; p = 0.047). The mean number of nebulizations per day of prn salbutamol was lower in the
BDP group as compared to the placebo group (0.26 and 0.34, respectively), but the difference was not significant
(p = 0.366). There were no differences in positive effects of BDP treatment between children with and without risk
factors for asthma.
Conclusions: A 1-week treatment with nebulized BDP and prn salbutamol is effective in increasing SFDs and
improving cough in children with wheezing, providing a clinical rationale for the short term use of ICS in episodic
wheeze exacerbations in pre-school children.
Trial Registration: ClinicalTrials.gov (NCT00497523)
Background
Wheezing is a common symptom in pre-school aged
children. Epidemiological studies have demonstrated
that approximately 30% of children have at least 1 epi-
sode of wheezing before the age of 3, with a cumulative
prevalence of wheezing of 50% at the age of 6 [1,2].
Most of these wheezing episodes are induced by viral
upper respiratory tract infections (RTI), which recur fre-
quently in this age group, and the great majority of
young children will have only transient symptoms with
no subsequent increased risko fa s t h m ao ra l l e r g yl a t e r
in life [1-3].
Recurrent pre-school wheezing is a very common clin-
ical problem, with important implications since it may
be associated in developed countries with a remarkable
impact on the healthcare budget [4]. Rates for wheez-
ing-related emergency room visits and hospitalizations
are highest among pre-school children, reflecting not
only the specific morbidity in this population, but also
the lack of conclusive evidence on the efficacy of avail-
able treatments/strategies for these acute events [4-6].
To date, the best treatment for children with intermit-
tent wheezing remains controversial.
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guidelines on the management of wheezing disorders in
pre-school children have been published [3,6-10]. For
persistent wheezing in children under the age of 5, low
dose inhaled corticosteroids (ICS) is recommended as
the preferred controller therapy, with leukotriene modi-
fiers as an alternative. Systematic reviews of controlled
trials evaluating the efficacy of ICS in infants/pre-
schoolers with wheeze or asthma showed that, in those
with frequent symptoms and/or with risk factors for
asthma, ICS therapy improves a variety of relevant out-
comes, including lung function and symptom-free days
(SFDs), wheeze/asthma exacerbation and need for sys-
temic glucocorticosteroids. In these studies, the benefi-
cial effect was independent of age, atopic condition, type
of ICS, mode of delivery and treatment duration
[3,11,12]. This is in agreement with the results of a ran-
domized controlled trial we recently published, in which
276 pre-school children (1-4 years of age) with a history
of recurrent wheezing, recruited during an acute wheez-
ing episode not requiring hospitalization or systemic
ICS, were randomly assigned to 3-month nebulized
treatments with: a) beclomethasone dipropionate (BDP)
b.i.d, plus prn (pro re nata) salbutamol; b) BDP/salbuta-
mol combination prn or c) prn salbutamol [13]. This
trial showed a higher percentage of SFDs in the sub-
group on regular nebulized BDP, as compared with prn
salbutamol. However there were no differences between
regular BDP and the prn combination subgroups on the
primary outcome measure (percentage of SFDs) as well
as on several secondary outcomes, such as symptom
scores, use of relief medication and exacerbation fre-
quency [13].
Systematic reviews and two recent reports have con-
cluded that episodic high-dose inhaled glucocorticoster-
oids may provide some benefit in episodic (viral) wheeze
[11,14-16] but, because of possible side effects (reduced
height) [16], the use of high-dose intermittent steroids
in this age group requires careful consideration [3,16].
Surprisingly, in contrast with the efficacy shown in med-
ium- long-term treatments, the efficacy of short-term
treatment with low-medium dose ICS is poorly documen-
ted in pre-school children with wheezing symptoms.
Here we report the results of a post-hoc analysis, per-
formed in our aforementioned study [13], to evaluate
whether low dose nebulized BDP (400 μg b.i.d), plus prn
salbutamol, was superior to nebulized prn salbutamol in
improving symptoms in the first week of treatment in
pre-school children with a history of recurrent wheez-
ing, recruited during an acute wheezing episode.
Methods
A detailed description of the study design, including
screening and recruitment procedures and statistical
analysis, has been reported in detail elsewhere [13] and
will only be briefly summarized.
Pre-school children (ages 1-4), with a documented his-
tory of at least 3 episodes of wheeze or asthma in the 6
months preceding the visit, evaluated as outpatients for
exacerbation of respiratory symptoms were screened
and characterized [13]. In addition to the three episodes
in the previous 6 months, the included children had a
history of frequent wheeze, induced by other triggers
than viral respiratory tract infection [3]. Nineteen pedia-
tric specialist care units were involved in this rando-
mized, multicenter, double blind, parallel-group,
placebo-controlled trial. Exclusion criteria were: a) his-
tory of severe exacerbations requiring systemic gluco-
corticoids; b) chest infection or hospitalization due to
asthma in the previous 4 weeks; c) treatment with
inhaled glucocorticoids or methyl-xanthine during the
previous 4 weeks; d) treatment with oral glucocorticoids
in the previous 8 weeks. Eligible children entered a 2-
week prospective open run-in period during which they
received only 2500 μg prn nebulized salbutamol for
symptom relief. Patients entered the double-blind treat-
m e n tp h a s ei ft h e yh a dw h e e z ea n d / o rc o u g h ,a n d / o r
shortness of breath, and/or required relief medication
on at least 7 days of the 2-week run-in period. The
study was performed in accordance with the Declaration
of Helsinki and Good Clinical Practice guidelines. Inde-
pendent ethics committees approved the study protocol,
patient information sheet, and consent forms. A parent
or guardian of each patient provided written informed
consent. Parents/guardians were trained: a) to correctly
use the nebulizer; b) to keep daily records of their
child’s symptoms, recording scores for wheeze, cough,
and shortness of breath on diary cards, using a four-
point rating scale ranging from 0 (no symptoms) to 3
(disabling symptom) [17]; c) to record the number of
occasions during the night they were woken up because
of the child’s asthma symptoms which required rescue
medication for symptom relief.
Children were stratified in two groups on the basis of
the presence or absence of risk factors for developing
persistent asthma [18]: (1) atopic dermatitis or eczema;
(2) asthma in a first-degree relative; (3) blood eosinophi-
lia > 4% demonstrated in the previous 6 months. A 2:1
treatment-to-placebo randomization ratio was used to
expose fewer patients to placebo.
In the original study [13], 3 treatments were tested in
this population over 12 weeks:
a) BDP (Clenil per Aerosol, Chiesi Farmaceutici,
Parma, Italy) 400 μg/vial, one vial b.i.d., plus salbutamol
(Ventmax, Chiesi Farmaceutici, Parma, Italy) 2500 μg/
vial, one vial prn, or b) placebo one vial b.i.d., plus fixed
combination of BDP and salbutamol (Clenil Composi-
tum, Chiesi Farmaceutici, Parma, Italy), 800 μgB D P+
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vial b.i.d. plus salbutamol 2500 μg/vial, one vial prn. All
drugs were delivered with the same nebulizer (Clenny
aerosol; Medel, Parma, Italy) using a tight-fitting face
mask.
In the current post-hoc analysis we compare the effi-
cacy of regular BDP plus prn salbutamol (BDP group)
vs. regular placebo plus prn salbutamol (placebo group)
on clinical outcomes captured in patients’ diaries during
the first week of treatment.
Groups were compared in terms of percentage of
SFDs at the end of 1-week treatment using an
ANCOVA model with percentage of SFDs as dependent
variable and treatment, country and subgroup as fixed
effects and baseline (run-in) as covariate. A day-by-day
analysis of the percentage of SFDs was also performed
using the same ANCOVA model.
Moreover, a comparison between groups within each
subgroup of the percentage of SFDs at the end of 1-
week treatment was performed using the same
ANCOVA model with also the subgroup*treatment
interaction as fixed effect.
The proportion of patients without asthma symptoms
during the first week of treatment was compared
between groups by means of a logistic regression model
with presence of symptoms during the first week as
dependent variable, treatment, country, subgroup and
percentage of SFDs during run-in as independent
variables.
Each of the three symptom scores was also analyzed
by means of a mixed model for repeated measures with
score at each day as dependent variable, treatment,
country, subgroup, day, treatment*day interaction and
mean value of symptoms during run-in as independent
variables. All tests were considered as explorative.
Results
One hundred sixty-six pre-school children, 98 males and
68 females, (between ages of 1-4) were included in the
post-hoc analysis: 110 were (64 (58.2%) males) in the
BDP group and 56 (34 (60.7%) males) in the placebo
group. The BDP group and the placebo group had simi-
lar baseline characteristics (table 1).
The adjusted mean percentage of SFDs (the study pri-
mary outcome [13]) at the end of the 7-day-treatment
was significantly higher in the BDP group (54.7%) than
in the placebo group (40.5%) (p = 0.012). The propor-
tion of patients without asthma symptoms during the
first week of treatment was significantly higher in the
BDP group than in the placebo group (odds ratio 2.65;
95% CI: 1.08, 6.51, p = 0.033). Day-by-day analysis
showed that the adjusted mean percentage of SFDs was
already higher after 2 days of treatment in the BDP
group (55.0%) as compared with the placebo group
(47.5%) with a 7.4% difference, the difference between
groups reaching statistical significance after 6 days of
treatment (52.4% in BDP group, 40.1% in placebo group
with a 12.3% difference, 95% CI of difference: 0.88, 23.8;
p = 0.035; Figure 1). At the end of the 7-day-treatment,
the adjusted mean coughing score was also lower in the
BDP group (0.11) compared to the placebo group (0.39)
with a difference of -0.29 (95% CI of difference: -0.568,
-0.002; p = 0.048); the between-group difference reached
statistical significance as early as day 5 of treatment (dif-
ference between BDP and placebo group is -0.29; p =
0.047; Figure 2). No significant differences were found
between the two groups with respect to other secondary
outcomes such as nocturnal awakenings, wheezing
score, shortness of breath score and symptom score (p >
0.05, all comparisons, data not shown) although all were
numerically in favour of BDP. The positive effects of
BDP treatment on percentage of SFDs were similar in
children with and without risk factors for asthma, the
difference in adjusted mean percentage of SFDs in the
first week of treatment being 2.06% (p = 0.75). Notably,
the difference between BDP and placebo was significant
in the subgroup of children with risk factors for asthma,
with 19.06% more SFDs as compared to placebo (p =
Table 1 Baseline characteristics
Beclomethasone (BDP group) (N = 110) Salbutamol (Placebo group) (N = 56)
Male, n (%) 64 (58.2) 34 (60.7)
Risk factors for asthma, n (%) 57 (51.8) 30 (53.6)
Age, yr 2.35 ± 0.81 2.29 ± 0.78
Weight, kg 15.4 ± 2.82 14.9 ± 2.74
Height, cm 97.5 ± 9.19 96.0 ± 9.61
Duration of wheezing, yr 1.59 ± 0.87 1.43 ± 0.82
Symptom-free days, % 21.4 ± 18.3 25.9 ± 21.0
Daily coughing score 1.43 ± 0.71 1.35 ± 0.80
Daily Salbutamol use, n
a 0.49 ± 0.48 0.42 ± 0.35
Values of symptom-free days, daily coughing score and daily salbutamol use are mean of the 2-week run-in period ± SD. Beclomethasone = beclomethasone
dipropionate;
a number of nebulizations per day.
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risk factors (p = 0.257) despite 9.24% more SFDs.
The adjusted mean number of nebulisations per day of
prn salbutamol was lower in the BDP group as com-
pared to the placebo group (0.26 and 0.34, respectively)
although the difference was not significant (p = 0.366).
Discussion
The results of this post-hoc analysis show the efficacy of
a short treatment with nebulized BDP in pre-school
children with a mild-to-moderate wheezing episode not
requiring hospitalization or systemic corticosteroids.
Previous studies on intermittent treatment with
inhaled glucocorticoids in pre-school wheeze exacerba-
tions led to conflicting results [3,11,12]. Three studies
suggested that initiating ICS therapy at the early signs of
episodic wheezing/asthma exacerbation in pre-school
children does not result in reduction in oral
corticosteroid use [19-21]. These studies, however, were
small and used different time points for intervening
with medication, thus limiting interpretation of results.
Also a study performed in 411 infants, enrolled at one
month of age to evaluate the effects of ICS initiated
after a three-day episode of wheezing, did not demon-
strate any short-term benefit during the acute manifes-
tation or on the progression from episodic to persistent
wheezing [22]. Lack of effect might be related to the
specific pathophysiology of wheezing episodes present in
young children.
More recently, Bacharier and co-workers, in a rando-
mized, double-blind, placebo-controlled trial compared
t h ee f f i c a c yo f7d a yt r e a t m e nt with either budesonide
inhalation suspension (1 mg twice daily), montelukast (4
mg daily), or placebo in addition to salbutamol at the
early signs of RTI in pre-school children with moderate-
to severe intermittent wheezing [15]. No differences in
the proportion of episode-free days, oral corticosteroid
and health care use, quality of life, or linear growth was
observed in the three treatment groups during the 12-
month trial. However, during RTI, administration of
budesonide and of montelukast led to significant reduc-
tion of episode severity as compared with conventional
therapy with reductions in trouble breathing and inter-
ference with activity scores. The efficacy was most evi-
dent during the peak symptom period of the first 48
hours of illness and in children with positive asthma
predictive indices [15,18].
Our results extend these observations showing the
efficacy of low dose nebulized BDP, detectable a few
days after the beginning of treatment. In contrast with
Bacharier’s study [15], we did not see any significant dif-
ference in the response to treatment between children
with positive or negative asthma predictive indices either
in the original 12-week trial or in this 1-week analysis.
This is in agreement with previous reports where no dif-
ferences in response to ICS were reported by pre-school
children with and without risk factors for asthma,
including atopic condition, sensitization to inhaled aller-
gens, and eczema [12,23,24]. Differences in the study
design and in the patient population may explain the
discrepancy between Bacharier’ss t u d y[ 1 5 ]a n do u r s .
Nevertheless, we found that the increase in the percen-
tage of SFDs after 1 week of BDP treatment, as com-
pared to placebo, was signific a n to n l yf o rt h es u b g r o u p
of children with risk factors.
Finally, an interesting hypothesis is that the episodic
use of an ICS (e.g. BDP) during acute RTI could
decrease an important source of future respiratory mor-
bidity, in these children, i.e. airway inflammation and
remodeling, leading to a medium-long-term down regu-
lation of the severity of the subsequent exacerbations
[13].
Figure 1 Percentage of symptom-free days in the first week of
treatment; each day represents the cumulative percentage of
symptom-free days in the preceding period; on day 1 the data
is relative to the % of symptom-free patients; * p < 0.05
between groups.
Figure 2 Mean coughing score in the first week of treatment;
each day represents the cumulative mean coughing score; * p
< 0,05 between groups.
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for asthma control and reflects the multiple components
of asthma disease burden. Although often informative in
comparing the effects of long-term controller medica-
tions for asthma in patients with chronic symptoms, it
has been shown to be also sufficiently sensitive to detect
treatment effects among children with an episodic disor-
der, such as severe intermittent asthma [15]. The
demonstration of the efficacy of a short treatment with
BDP in the present trial is of interest even from a safety
point of view, considering that we detected no systemic
effects of the 12 weeks treatment in the original trial by
measuring cortisol at the beginning and end of treat-
ment [13]. The systemic side effects of corticosteroids
are considered negligible in short term therapies but
this is in contrast with recent findings. A study evaluat-
ing the immune response of children aged three to 17,
arriving at the emergency room with an asthma attack
showed an immune suppression in children receiving
oral corticosteroids [25]. In light of this new evidence,
the use of nebulized rather than oral corticosteroids
may be preferable even for short term treatments.
The limit of the present study is that the post-hoc
analyses were based only on the data of the first week of
a 3-month clinical trial and P-values of these analyses
were unadjusted for multiplicity.
Conclusions
In conclusion, this study shows the short term efficacy
of a one week nebulized BDP plus salbutamol as needed
treatment on SFDs and coughing in young children with
wheezing. Our findings, along with recent pharmacolo-
gical reports showing the rapid onset of action of ICS
[26,27] could provide a clinical rationale for the short
term use of ICS in episodic wheeze, one of the most fre-
quent recurrent respiratory disorders in pre-school
children.
Acknowledgements
Investigators of the BEST for CHILDREN study group were: Dr Henryk
Mazurek, Dr Marcin Wronski, Dr Jolanta Pietraszek-Mamcarz, Dr Agata
Swierczek, Dr Jadwiga Kaczmarek and Prof. Jerzy Hofman from Poland; Prof.
Olga Illarionovna Lasytsya, Prof. Aryayev Nikolay Leonidovich, Prof. Viktoria
Pavlovna Kostromina, Prof. Senatorova Anna Sergeyivna, Prof. Kobets Tatyana
Vladimirovna, Prof. Antypkyn Yuriy Genadievich, Prof. Lapshyn Vladymir
Fedorovych, Dr Tatyana Ivanovna Okul, Prof. Svetlana Alexeevna Mokia-
Serbina, Prof. Ekaterina Dmitrievna Duka, Prof. Leonid Sergeevich
Ovcharenko, Prof. Tatyana Alexandrovna Kryuchko and Prof. Lyudmila
Vladimirovna Vashchenko from Ukraine.
The study was funded by Chiesi Farmaceutici SpA, Parma, Italy
Author details
1Department of Respiratory Diseases, Research Centre on Asthma and COPD,
University of Ferrara, Ferrara, Italy.
2Medical Department, Chiesi Farmaceutici,
Parma, Italy.
3Department of Pediatrics, University of Verona, Verona, Italy.
4Department of Pediatrics, Unit of Allergy and Respiratory Medicine,
University of Padova, Padova, Italy.
5Department of Pediatrics, Ospedale
Pediatrico Bambino Gesù, Roma, Italy.
6Department of Respiratory Diseases,
University of Modena, Modena, Italy.
7Department of Pediatrics, Ospedale
Gaslini, Genova, Italy.
Authors’ contributions
AP, GN and GAR contributed to designing the study, data analysis and
writing the manuscript; ALB, EB, RC and LMF contributed to data analysis
and interpretation and writing the manuscript. All authors read and
approved the final manuscript.
Competing interests
AP, ALB, EB, RC, LMF and GAR declare no conflict of interest. GN is a Chiesi
Farmaceutici employee.
Received: 11 May 2011 Accepted: 22 August 2011
Published: 22 August 2011
References
1. Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ:
Asthma and wheezing in the first six years of life. N Engl J Med 1995,
332:133-138.
2. Bisgaard H, Szefler S: Prevalence of asthma-like symptoms in young
children. Pediatr Pulmonol 2007, 42:723-728.
3. Brand PL, Baraldi E, Bisgaard H, Boner AL, Castro-Rodriguez JA, Custovic A,
de Blic J, de Jongste JC, Eber E, Everard ML, Frey U, Gappa M, Garcia-
Marcos L, Grigg J, Lenney W, Le Souëf P, McKenzie S, Merkus PJ, Midulla F,
Paton JY, Piacentini G, Pohunek P, Rossi GA, Seddon P, Silverman M, Sly PD,
Stick S, Valiulis A, van Aalderen WM, Wildhaber JH, Wennergren G,
Wilson N, Zivkovic Z, Bush A: Definition, assessment and treatment of
wheezing disorders in preschool children: an evidence-based approach.
Eur Respir J 2008, 32:1096-110.
4. Stevens CA, Turner D, Kuehni CE, Couriel JM, Silverman M: The economic
impact of preschool asthma and wheeze. Eur Respir J 2003, 21:1000-1006.
5. Akinbami LJ, Schoendorf KC: Trends in childhood asthma:prevalence,
health care utilization, and mortality. Pediatrics 2002, 110:315-22.
6. Global Strategy for the Diagnosis and Management of Asthma in
Children 5 Years and Younger 2009. [http://www.ginasthma.org].
7. British Thoracic Society, Scottish Intercollegiate Guidelines Network: British
guideline on the managementof asthma. Thorax 2003, 58(Suppl 1):i1-i94.
8. National Heart Lung and Blood Institute, National Asthma Education and
Prevention Program: Expert Panel Report 3:Guidelines for the Diagnosis
and Management of Asthma. Bethesda, National Heart, Lung and Blood
Institute 2007.
9. Kuehni CE: Phenotype specific treatment of obstructive airways disease
in infancy and childhood:new recommendations of the Swiss Paediatric
Pulmonology Group. Swiss Med Wkly 2005, 135:95-100.
10. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M,
Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P,
Simons FE, Valovirta E, Wahn U, Wildhaber J, European Pediatric Asthma
Group: Diagnosis and treatment of asthma in childhood: a PRACTALL
consensus report. Allergy 2008, 63:5-34.
11. Kaditis AG, Winnie G, Syrogiannopoulos GA: Anti-inflammatory
pharmacotherapy for wheezing in preschool children. Pediatr Pulmonol
2007, 42:407-20.
12. Castro-Rodriguez JA, Rodrigo GJ: Efficacy of inhaled corticosteroids in
infants and preschoolers with recurrent wheezing and asthma: a
systematic review with meta-analysis. Pediatrics 2009, 123:519-25.
13. Papi A, Nicolini G, Baraldi E, Boner AL, Cutrera R, Rossi GA, Fabbri LM:
Regular vs prn nebulized treatment in wheeze preschool children. Allergy
2009, 64:1463-71.
14. McKean M, Ducharme F: Inhaled steroids for episodic viral wheeze of
childhood. Cochrane Database Syst Rev 2000, , 1: CD001107.
15. Bacharier LB, Phillips BR, Zeiger RS, Szefler SJ, Martinez FD, Lemanske RF Jr,
Sorkness CA, Bloomberg GR, Morgan WJ, Paul IM, Guilbert T, Krawiec M,
Covar R, Larsen G, Mellon M, Moss MH, Chinchilli VM, Taussig LM,
Strunk RC, CARE Network: Episodic use of an inhaled corticosteroid or
leukotriene receptor antagonist in preschool children with moderate-to-
severe intermittent wheezing. J Allergy Clin Immunol 2008, 122:1127-1135.
16. Ducharme FM, Lemire C, Noya FJ, Davis GM, Alos N, Leblond H, Savdie C,
Collet JP, Khomenko L, Rivard G, Platt RW: Preemptive use of high-dose
fluticasone for virus-induced wheezing in young children. N Engl J Med
2009, 360:339-53.
Papi et al. Italian Journal of Pediatrics 2011, 37:39
http://www.ijponline.net/content/37/1/39
Page 5 of 617. Bisgaard H, Gillies J, Groenewald M, Maden C: The effect of inhaled
fluticasone propionate in the treatment of young asthmatic children: a
dose comparison study. Am J Respir Crit Care Med 1999, 160:126-131.
18. Castro-Rodriguez JA, Holberg CJ, Wright AL, Martinez FD: A clinical index
to define risk of asthma in young children with recurrent wheezing. Am
J Respir Crit Care Med 2000, 162:1403-140.
19. Wilson N, Silverman M: Treatment of acute, episodic asthma in preschool
children using intermittent high dose inhaled steroids at home. Arch Dis
Child 1990, 65:407-10.
20. Connett G, Lenney W: Prevention of viral induced asthma attacks using
inhaled budesonide. Arch Dis Child 1993, 68:85-7.
21. Svedmyr J, Nyberg E, Thunqvist P, Asbrink-Nilsson E, Hedlin G: Prophylactic
intermittent treatment with inhaled corticosteroids of asthma
exacerbations due to airway infections in toddlers. Acta Paediatr 1999,
88:42-7.
22. Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F: Intermittent
inhaled corticosteroids in infants with episodic wheezing. N Engl J Med
2006, 354:1998-2005.
23. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ,
Bacharier LB, Lemanske RF Jr, Strunk RC, Allen DB, Bloomberg GR, Heldt G,
Krawiec M, Larsen G, Liu AH, Chinchilli VM, Sorkness CA, Taussig LM,
Martinez FD: Long-term inhaled corticosteroids in preschool children at
high risk for asthma. N Engl J Med 2006, 354:1985-1997.
24. Campusano L, Pastenes M, Fontecilla C, Escalona J, Salazar C, Castro-
Rodriguez JA: Response to budesonide among atopic and non-atopic
infants/preschoolers with recurrent wheezing. Allergol Immunopathol
2010, 38:31-6.
25. Ducharme Francine M, Ochs Hans D, Sandy Resendes, Xun Zhang, Bruce D,
Mazer A: Short Burst of Oral Corticosteroid for Children with Acute
Asthma: Is There an Impact on Immunity? PEDIATRIC ALLERGY,
IMMUNOLOGY, AND PULMONOLOGY Volume 23, Number 4 2010.
26. Spallarossa D, Battistini E, Silvestri M, Sabatini F, Biraghi MG, Rossi GA: Time-
dependent changes in orally exhaled nitric oxide and pulmonary
functions induced by inhaled corticosteroids in childhood asthma. J
Asthma 2001, 38:545-535.
27. Papi A, Caramori G, Adcock IM, Barnes PJ: Rescue treatment in asthma.
More than as-needed bronchodilation. Chest 2009, 135:1628-33.
doi:10.1186/1824-7288-37-39
Cite this article as: Papi et al.: Short term efficacy of nebulized
beclomethasone in mild-to-moderate wheezing episodes in pre-school
children. Italian Journal of Pediatrics 2011 37:39.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Papi et al. Italian Journal of Pediatrics 2011, 37:39
http://www.ijponline.net/content/37/1/39
Page 6 of 6